Status:
COMPLETED
Caffeine and Cerebrovascular Reactivity
Lead Sponsor:
University of Oklahoma
Conditions:
Caffeine
Eligibility:
All Genders
21-85 years
Phase:
EARLY_PHASE1
Brief Summary
Caffeine is the most commonly used stimulant drug with well documented effects on cerebral vascula-ture. Caffeine is known to non-specifically bind to adenosine receptors in the brain and to reduce re...
Detailed Description
Normal brain function is critically dependent on moment-to-moment adjustment of cerebral blood flow to match demands of activated neurons. This process is known as neurovascular coupling (NVC) and rec...
Eligibility Criteria
Inclusion
- English speaking
- Ability to read and write in English
- Competence to provide informed consent
- Non-occludable angle and with no optic neuropathy
- Subjects will be asked to refrain from caffeine consumption for at least 8 hours before participating in the study
Exclusion
- The history of photosensitive epilepsy
- Intraocular pressure 21 Hgmm or higher
- Eyes with a visual acuity 20/30 or lower or the inability to fixate on fixation markers
- Previous symptoms of glaucoma attack (severe ocular pain and redness, decreased vision, colored halos in combination with headache, nausea and vomiting).
- Known allergies to study drugs
- Pregnancy and breast feeding
- Significant cardiac disease (e.g. heart failure), chest pain in the last 6 months
- Stage-2 high blood pressure not controlled by medication (\>160/100 mm Hg)
- Uncontrolled diabetes mellitus; History of stroke; Multiple sclerosis; Chronic obstructive pulmonary disease; Active cancer; Abnormal liver function
- Diagnosis of dementia; Anxiety Disorder
- Absent temporal acoustic windows, intracranial stenosis (for TCD-related studies)
- History of arrhythmias
- Prisoners
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2022
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04730193
Start Date
February 1 2021
End Date
August 1 2022
Last Update
August 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Translational GeroScience Laboratory
Oklahoma City, Oklahoma, United States, 73117